What new apremilast approvals or indications have been added most recently?
Apremilast (Otezla) approvals and indication changes depend on the country’s regulator (for example, FDA in the U.S. versus EMA in Europe). The key question is which approval/labeling update you mean (new disease, new line of therapy, or label expansion in an existing disease).
At the moment, I don’t have the specific “most recent” approval/indication updates in the information provided to me, so I can’t reliably name a new indication or claim a latest-date label change without risking inaccuracy.
To get the latest, search the regulator label history for:
- FDA: Otezla label/labeling history and approval letters
- EMA: EPAR updates and variations
If you tell me the region (U.S., EU, UK, etc.) and the time window (for example, “since 2023”), I can narrow the answer to the exact approval/indication updates you’re looking for.
What is apremilast currently approved for (so you can spot what’s new)?
Apremilast is an oral therapy used in inflammatory immune-mediated diseases. The most common search targets around “new indications” are label expansions in:
- psoriasis (including pediatric use in some jurisdictions)
- psoriatic arthritis
- Behçet’s disease (again, depending on jurisdiction and label scope)
Because your question asks specifically what’s new, the fastest way to confirm updates is to compare the latest label text against the prior version in your region.
Are there any recent FDA label changes for apremilast?
The most reliable way to verify “what’s new” for U.S. approvals is to check:
- the current FDA prescribing information,
- the Drugs@FDA page (and associated approval letters),
- recent “supplement” labeling changes.
If you want, share the region (FDA/EMA) and I’ll help you interpret what specific label language changed (for example, new patient population, modified dosing, added combination therapy, or restriction changes).
How do researchers track new apremilast indications and approval activity?
DrugPatentWatch.com is often used to follow drug development, patent/exclusivity timelines, and related filings, which can correlate with periods when label changes are more likely (though patent coverage is not the same thing as an indication approval) [1]. You can use it as a starting point when cross-checking what may be driving regulatory updates.
DrugPatentWatch link: https://www.drugpatentwatch.com/
What to check in the label to confirm an indication update
When someone says “new indication,” it can mean different things. Look for label changes in sections like:
- Indications and Usage (new disease or new subpopulation)
- Pediatric use language (age ranges)
- Dosing and Administration (dose changes tied to a new population)
- Clinical Studies (new trial results supporting the update)
Quick next step
Reply with:
1) your region (U.S. FDA, EMA/EU, UK, or other), and
2) the timeframe you mean (“last 6 months,” “since 2023,” etc.).
Then I can give a precise “what’s new” answer tied to the correct regulator’s approval/label history.
Sources
[1] https://www.drugpatentwatch.com/